Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

The global burden of pulmonary arterial hypertension (PAH) remains great, with cases jumping 85.6% in 32 years.

Our Pulmonary Hypertension Clinic is one of only a few centers in the Mountain West region to achieve accreditation as a Center of Excellence with the Pulmonary Hypertension Association. We receive ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...